• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Emergent BioSolutions Announces Appointment of Sujata Dayal to Board of Directors

    7/6/22 4:05:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EBS alert in real time by email

    GAITHERSBURG, Md., July 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company's board of directors appointed Sujata Dayal as a Class II director to serve on the board effective July 15, 2022, with an initial term expiring at the 2023 annual meeting of stockholders. Ms. Dayal was also appointed as a member of both the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight.

    "We are pleased to welcome Sujata Dayal to Emergent's Board of Directors," said Zsolt Harsanyi, Ph.D., chairman of the board of Emergent BioSolutions. "Sujata's deep experience in healthcare compliance and strong expertise in legal and regulatory oversight will be invaluable to Emergent as we continue to grow the business and pursue our mission. We look forward to her contributions."

    "I am enthusiastic to serve on the board of a company that is focused on public health with a mission to protect and enhance life," said Ms. Dayal. "As Emergent executes on its strategy, I am delighted with the opportunity to contribute my passions in healthcare compliance and working with fellow directors and the management team to advance the company."

    Ms. Dayal has served as vice president and global chief compliance officer of Medline Industries, Inc. since March 2020. Over the last two decades, Ms. Dayal has held roles of growing responsibility in compliance with a focus on healthcare compliance in the pharmaceutical and medical device industry. She previously served as a vice president, healthcare compliance at Johnson & Johnson from 2013 to 2020. Prior to that, she served on senior executive roles in ethics and compliance at Biomet, Inc. and Abbott Laboratories.

    Ms. Dayal is an attorney by training with expertise in transactional work, regulatory law, privacy and compliance, including healthcare compliance and anti-corruption. She earned her J.D. from Chicago-Kent College of Law, LL.M. from Columbia University School of Law, LL.B. from Rajasthan University Law School in Jaipur, India, and B.A. Honors degree in Political Science from Lady Shri Ram College in New Delhi, India.

    About Emergent BioSolutions

    At Emergent, our mission is to protect and enhance life. For over 20 years, we've been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, Twitter, and Instagram.

    Safe Harbor Statement

    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, but no limited to, statements regarding executing on our growth strategy and advancing the company, are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances. There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements. Investors should consider this cautionary statement as well as the risk factors identified in our periodic reports filed with the Securities and Exchange Commission when evaluating our forward-looking statements.

    Investor Contact:

    Robert G. Burrows

    Vice President, Investor Relations

    240-631-3280

    [email protected]

    Media Contact:

    Matt Hartwig

    Senior Director, Media Relations

    [email protected]



    Primary Logo

    Get the next $EBS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EBS

    DatePrice TargetRatingAnalyst
    12/30/2024$15.00Buy
    H.C. Wainwright
    8/22/2024$16.00Buy
    Rodman & Renshaw
    3/7/2024$5.00Hold → Buy
    The Benchmark Company
    11/20/2023Underweight
    JP Morgan
    8/29/2023Buy → Hold
    The Benchmark Company
    4/10/2023$22.00Hold → Buy
    The Benchmark Company
    3/17/2023$23.00 → $9.00Neutral → Underweight
    JP Morgan
    11/10/2022Buy → Hold
    The Benchmark Company
    More analyst ratings

    $EBS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Emergent BioSolutions with a new price target

      H.C. Wainwright initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $15.00

      12/30/24 7:24:57 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on Emergent BioSolutions with a new price target

      Rodman & Renshaw initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $16.00

      8/22/24 7:22:39 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions upgraded by The Benchmark Company with a new price target

      The Benchmark Company upgraded Emergent BioSolutions from Hold to Buy and set a new price target of $5.00

      3/7/24 10:14:18 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EBS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Emergent BioSolutions Reports First Quarter 2025 Financial Results

      First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior yearFirst Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior yearFirst Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 500 bps and 700 bps, respectively, versus prior yearFirst Quarter 2025 Adjusted EBITDA of $77.6 million, increase of 16% versus prior yearFirst Quarter 2025 Adjusted EBITDA Margin of 35% of Total Revenues, an improvement of 1,300 bps versus prior yearReaffirmed FY 2025 Guidance GAITHERSBURG, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the first quarter ended March 

      5/7/25 4:05:00 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

      WINNIPEG, Manitoba, May 01, 2025 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE:EBS) announced a maximum three-year agreement with a value of approximately $65 million to supply the Ontario Ministry of Health with NARCAN® Nasal Spray for the Ontario Naloxone Program (ONP). Since 2018, Emergent has supported the Ontario Ministry of Health to provide access to NARCAN® Nasal Spray across the province. NARCAN® Nasal Spray is designed to reverse the effects of an opioid poisoning in minutes and is the only 4 mg, intranasal naloxone spray in Canada with a shelf life of four years (48 months). From January through March 2025, there were 653 suspect drug-related fatalities in Ontario

      5/1/25 5:07:20 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

      GAITHERSBURG, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, May 7, 2025, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2025. Participants can access the conference call live via webcast, and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can be a

      4/22/25 8:00:00 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EBS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Emergent BioSolutions Inc.

      SC 13G - Emergent BioSolutions Inc. (0001367644) (Subject)

      11/13/24 4:00:18 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Emergent BioSolutions Inc.

      SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)

      11/8/24 5:23:28 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Emergent BioSolutions Inc.

      SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)

      9/10/24 12:09:00 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EBS
    Leadership Updates

    Live Leadership Updates

    See more
    • Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

      Executive Management Team appointments contribute to Emergent's transformation and beyond, including promotion of Jessica Perl to General Counsel and Corporate Secretary GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced the appointment of Simon Lowry, M.D., as chief medical officer, head of research and development, effective November 18. Dr. Lowry will be responsible for advancing Emergent's strategic scientific roadmap, and will oversee research and development, regulatory affairs, medical affairs, clinical an

      11/4/24 7:30:00 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic

      Ongoing support of the ‘White House Challenge to Save Lives from Overdose' through workplace and public safety measuresOne-year mark of Ready to Rescue public awareness campaign to expand awareness, particularly among young adults and vulnerable communities20,000 additional doses of NARCAN® Nasal Spray to be donated to organizations in need GAITHERSBURG, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) remains committed to supporting widespread opioid emergency preparedness by expanding access to NARCAN® Nasal Spray and educating the public on how to respond to an opioid overdose. As opioid overdose fatalities have risen in the workplace in recent years,1 Emerg

      10/8/24 5:32:28 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

      MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro

      9/4/24 8:00:00 AM ET
      $CADL
      $EBS
      $MIST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $EBS
    Financials

    Live finance-specific insights

    See more
    • Emergent BioSolutions Reports First Quarter 2025 Financial Results

      First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior yearFirst Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior yearFirst Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 500 bps and 700 bps, respectively, versus prior yearFirst Quarter 2025 Adjusted EBITDA of $77.6 million, increase of 16% versus prior yearFirst Quarter 2025 Adjusted EBITDA Margin of 35% of Total Revenues, an improvement of 1,300 bps versus prior yearReaffirmed FY 2025 Guidance GAITHERSBURG, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the first quarter ended March 

      5/7/25 4:05:00 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

      GAITHERSBURG, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, May 7, 2025, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2025. Participants can access the conference call live via webcast, and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can be a

      4/22/25 8:00:00 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

      Fourth Quarter 2024 Total Revenues of $194.7 million; Full Year 2024 Total Revenues of $1.04 billionFourth Quarter 2024 Net Loss of $31.3 million, decrease in Net Loss of 37% versus prior yearFourth Quarter 2024 Adjusted EBITDA of $21.0 million, increase of 518% versus prior yearFull Year 2024 Adjusted EBITDA of $183.1 million, compares favorably to a loss of $22.3 million in 2023Guiding to 2025 Adjusted EBITDA of $150 - $200 million and improved gross margins GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the quarter and year ended December 31, 2024. "As we close out 2024, I'm proud to share we delivered f

      3/3/25 4:23:24 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Richard Ronald was granted 34,403 shares, increasing direct ownership by 48% to 105,517 units (SEC Form 4)

      4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

      5/2/25 8:31:43 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director White Marvin L was granted 34,403 shares, increasing direct ownership by 64% to 88,495 units (SEC Form 4)

      4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

      5/2/25 8:31:33 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fowler Neal Franklin was granted 34,403 shares, increasing direct ownership by 34% to 135,503 units (SEC Form 4)

      4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

      5/2/25 8:31:22 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EBS
    SEC Filings

    See more
    • Emergent BioSolutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Emergent BioSolutions Inc. (0001367644) (Filer)

      5/7/25 4:08:56 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Emergent BioSolutions Inc. (0001367644) (Filer)

      5/6/25 4:19:14 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Emergent BioSolutions Inc. (0001367644) (Filer)

      3/31/25 8:06:39 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care